Under the sunlight of government incentives for development, the current crop of antifungal drugs is looking encouraging to infectious disease researchers, with improvements on old classes and a range of new targets emerging.
Pipeline Update: New Antifungals Sprout In Warmer Regulatory Climate
Candidates from Cidara, Scynexis, Viamet and more featured in a symposium at the ICAAC/ICC meeting in September.